Published in Int J Radiat Oncol Biol Phys on March 01, 2010
Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT. Int J Radiat Oncol Biol Phys (2015) 2.12
Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer (2013) 2.10
Standardizing naming conventions in radiation oncology. Int J Radiat Oncol Biol Phys (2012) 1.70
Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. Int J Radiat Oncol Biol Phys (2012) 1.70
New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci Transl Med (2013) 1.35
Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31
Post-radioembolization yttrium-90 PET/CT - part 2: dose-response and tumor predictive dosimetry for resin microspheres. EJNMMI Res (2013) 1.14
The physical basis and future of radiation therapy. Br J Radiol (2011) 0.99
Organ-sparing radiation therapy for head and neck cancer. Nat Rev Clin Oncol (2011) 0.99
Doses in organs at risk during head and neck radiotherapy using IMRT and 3D-CRT. Radiol Oncol (2012) 0.96
IsoBED: a tool for automatic calculation of biologically equivalent fractionation schedules in radiotherapy using IMRT with a simultaneous integrated boost (SIB) technique. J Exp Clin Cancer Res (2011) 0.93
The tolerance of gastrointestinal organs to stereotactic body radiation therapy: what do we know so far? J Gastrointest Oncol (2014) 0.93
Dose-volume-related dysphagia after constrictor muscles definition in head and neck cancer intensity-modulated radiation treatment. Br J Radiol (2014) 0.92
Re-irradiation of recurrent head and neck carcinomas: comparison of robust intensity modulated proton therapy treatment plans with helical tomotherapy. Radiat Oncol (2013) 0.91
Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective. Front Oncol (2014) 0.91
Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer. J Thorac Dis (2014) 0.91
Trial Watch: Radioimmunotherapy for oncological indications. Oncoimmunology (2014) 0.91
Development of a novel animal model to differentiate radiation necrosis from tumor recurrence. J Neurooncol (2012) 0.90
Predictors of high-grade esophagitis after definitive three-dimensional conformal therapy, intensity-modulated radiation therapy, or proton beam therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys (2012) 0.89
Volumetric modulated arc radiotherapy sparing the thyroid gland for early-stage glottic cancer: A dosimetrical analysis. Oncol Lett (2014) 0.89
Technical guidelines for head and neck cancer IMRT on behalf of the Italian association of radiation oncology - head and neck working group. Radiat Oncol (2014) 0.88
Excellent local control and survival after postoperative or definitive radiation therapy for sarcomas of the head and neck. Radiat Oncol (2015) 0.88
Stereotactic radiation therapy for skull base recurrences: Is a salvage approach still possible? Rep Pract Oncol Radiother (2014) 0.88
Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. Int J Cancer (2014) 0.88
Minimally invasive local therapies for liver cancer. Cancer Biol Med (2014) 0.88
Radiation myelitis after hypofractionated radiotherapy with concomitant gefitinib. Radiat Oncol (2015) 0.87
Whole brain radiotherapy for brain metastasis. Surg Neurol Int (2013) 0.87
Complication probability models for radiation-induced heart valvular dysfunction: do heart-lung interactions play a role? PLoS One (2014) 0.86
Cardiac Exposure in the Dynamic Conformal Arc Therapy, Intensity-Modulated Radiotherapy and Volumetric Modulated Arc Therapy of Lung Cancer. PLoS One (2015) 0.86
Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for stage I-II natural killer/T-cell lymphoma nasal type: dosimetric and clinical results. Radiat Oncol (2013) 0.85
Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol (2015) 0.85
Therapeutic application of CCK2R-targeting PP-F11: influence of particle range, activity and peptide amount. EJNMMI Res (2014) 0.85
The impact of flattening-filter-free beam technology on 3D conformal RT. Radiat Oncol (2013) 0.85
Stereotactic body radiotherapy for Stage I lung cancer with chronic obstructive pulmonary disease: special reference to survival and radiation-induced pneumonitis. J Radiat Res (2015) 0.85
Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. J Clin Oncol (2016) 0.85
Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma. Surg Today (2016) 0.84
Feasibility of extreme dose escalation for glioblastoma multiforme using 4π radiotherapy. Radiat Oncol (2014) 0.84
Toxicity outcome in patients treated with modulated arc radiotherapy for localized prostate cancer. Rep Pract Oncol Radiother (2013) 0.84
Planning comparison between standard and conformal 3D techniques in post-operative radiotherapy of gastric cancer: a systematic review. Br J Radiol (2013) 0.84
Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control. Radiat Oncol (2013) 0.83
Empirical estimation of beam-on time for prostate cancer patients treated on Tomotherapy. Rep Pract Oncol Radiother (2013) 0.82
Clinical implications in the use of the PBC algorithm versus the AAA by comparison of different NTCP models/parameters. Radiat Oncol (2013) 0.82
Concept for individualized patient allocation: ReCompare--remote comparison of particle and photon treatment plans. Radiat Oncol (2014) 0.82
Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate. Eur J Nucl Med Mol Imaging (2016) 0.81
Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology (2016) 0.81
USP9X inhibition promotes radiation-induced apoptosis in non-small cell lung cancer cells expressing mid-to-high MCL1. Cancer Biol Ther (2015) 0.81
Radiobiological model-based bio-anatomical quality assurance in intensity-modulated radiation therapy for prostate cancer. J Radiat Res (2012) 0.81
A simple plan evaluation index based on the dose to critical structures in radiotherapy. J Med Phys (2011) 0.81
New approach for treatment of vertebral metastases using intensity-modulated radiotherapy. Strahlenther Onkol (2011) 0.80
Radiation pneumonitis and pulmonary function with lung dose-volume constraints in breast cancer irradiation. J Radiother Pract (2013) 0.80
Intensity-Modulated Radiotherapy versus 3-Dimensional Conformal Radiotherapy Strategies for Locally Advanced Non-Small-Cell Lung Cancer. Balkan Med J (2014) 0.80
A prospective cohort study on postoperative radiotherapy with TomoDirect using simultaneous integrated boost technique in early breast cancer. Radiat Oncol (2014) 0.80
INTRAGO: intraoperative radiotherapy in glioblastoma multiforme—a phase I/II dose escalation study. BMC Cancer (2014) 0.80
Accumulated dose to the rectum, measured using dose-volume histograms and dose-surface maps, is different from planned dose in all patients treated with radiotherapy for prostate cancer. Br J Radiol (2015) 0.80
Big Data Analytics for Prostate Radiotherapy. Front Oncol (2016) 0.80
Feasibility and efficacy of simultaneous integrated boost intensity-modulated radiation therapy in patients with limited-disease small cell lung cancer. Radiat Oncol (2014) 0.80
Effect of the Maximum Dose on White Matter Fiber Bundles Using Longitudinal Diffusion Tensor Imaging. Int J Radiat Oncol Biol Phys (2016) 0.80
Individualised (177)Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging (2017) 0.79
A predictive model to guide management of the overlap region between target volume and organs at risk in prostate cancer volumetric modulated arc therapy. Radiat Oncol J (2014) 0.79
Whole brain helical Tomotherapy with integrated boost for brain metastases in patients with malignant melanoma-a randomized trial. Radiat Oncol (2013) 0.79
Low rate of lymphedema after extended pelvic lymphadenectomy followed by pelvic irradiation of node-positive prostate cancer. Radiat Oncol (2013) 0.79
Toward a planning scheme for emission guided radiation therapy (EGRT): FDG based tumor tracking in a metastatic breast cancer patient. Med Phys (2013) 0.79
Retrospective evaluation of dosimetric quality for prostate carcinomas treated with 3D conformal, intensity modulated and volumetric modulated arc radiotherapy. J Med Radiat Sci (2013) 0.79
Proposal of a post-prostatectomy clinical target volume based on pre-operative MRI: volumetric and dosimetric comparison to the RTOG guidelines. Radiat Oncol (2014) 0.79
Normal tissue complication probability (NTCP) modelling using spatial dose metrics and machine learning methods for severe acute oral mucositis resulting from head and neck radiotherapy. Radiother Oncol (2016) 0.79
Dosimetric impact in the dose-volume histograms of rectal and vesical wall contouring in prostate cancer IMRT treatments. Rep Pract Oncol Radiother (2017) 0.78
Differences in rates of radiation-induced true and false rib fractures after stereotactic body radiation therapy for Stage I primary lung cancer. J Radiat Res (2014) 0.78
Postradiation imaging changes in the CNS: how can we differentiate between treatment effect and disease progression? Future Oncol (2014) 0.78
Adjuvant chemotherapy and acute toxicity in hypofractionated radiotherapy for early breast cancer. World J Clin Cases (2014) 0.78
Use of gEUD for predicting ear and pituitary gland damage following proton and photon radiation therapy. Br J Radiol (2015) 0.78
The different dose-volume effects of normal tissue complication probability using LASSO for acute small-bowel toxicity during radiotherapy in gynecological patients with or without prior abdominal surgery. Biomed Res Int (2014) 0.78
The impact of direct aperture optimization on plan quality and efficiency in complex head and neck IMRT. Radiat Oncol (2012) 0.78
Feasibility of the partial-single arc technique in RapidArc planning for prostate cancer treatment. Chin J Cancer (2013) 0.78
Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity (86)Y- or (177)Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates. Eur J Nucl Med Mol Imaging (2015) 0.78
Iodine-125 prostate seed brachytherapy in renal transplant recipients: an analysis of oncological outcomes and toxicity profile. J Contemp Brachytherapy (2014) 0.78
Dosimetric analysis of radiation-induced gastric bleeding. Int J Radiat Oncol Biol Phys (2012) 0.78
Dosimetric comparison of axilla and groin radiotherapy techniques for high-risk and locally advanced skin cancer. Radiat Oncol J (2016) 0.78
Acute small-bowel toxicity during neoadjuvant combined radiochemotherapy in locally advanced rectal cancer: determination of optimal dose-volume cut-off value predicting grade 2-3 diarrhoea. Radiat Oncol (2015) 0.78
Increased risk of death due to heart disease after radiotherapy for esophageal cancer. J Gastrointest Oncol (2015) 0.77
Comparison of once daily radiotherapy to 60 Gy and twice daily radiotherapy to 45 Gy for limited stage small-cell lung cancer. Thorac Cancer (2015) 0.77
Advancing our quantitative understanding of radiotherapy normal tissue morbidity. Acta Oncol (2014) 0.77
Contribution of three-dimensional conformal intensity-modulated radiation therapy for women affected by bulky stage II supradiaphragmatic Hodgkin disease. Radiat Oncol (2013) 0.77
Brachial plexus dose tolerance in head and neck cancer patients treated with sequential intensity modulated radiation therapy. Radiat Oncol (2015) 0.77
Evaluation of acute/late toxicity and local recurrence in T1-T2 glottic carcinoma treated with accelerated hypofractionated 3D-conformal external beam radiotherapy (3D-CRT). Radiol Oncol (2013) 0.77
Stereotactic body radiotherapy as primary therapy for head and neck cancer in the elderly or patients with poor performance. Front Oncol (2014) 0.77
Comparing treatment plan in all locations of esophageal cancer: volumetric modulated arc therapy versus intensity-modulated radiotherapy. Medicine (Baltimore) (2015) 0.77
Mechanistic modelling of radiotherapy-induced lung toxicity. Br J Radiol (2012) 0.77
Delayed radiation-induced inflammation accompanying a marked carbohydrate antigen 19-9 elevation in a patient with resected pancreatic cancer. Radiat Oncol J (2016) 0.77
Geometric dose prediction model for hemithoracic intensity-modulated radiation therapy in mesothelioma patients with two intact lungs. J Appl Clin Med Phys (2016) 0.77
Radiation sparing of cerebral cortex in brain tumor patients using quantitative neuroimaging. Radiother Oncol (2016) 0.76
Prognostic Significance of Serum Inflammatory Response Markers in Newly Diagnosed Non-Small Cell Lung Cancer before Chemoirradiation. Biomed Res Int (2015) 0.76
Intensity modulated radiotherapy of upper abdominal malignancies: dosimetric comparison with 3D conformal radiotherapy and acute toxicity. Radiat Oncol (2013) 0.76
The relationship between thyroid dose and diagnosis of primary hypothyroidism in pediatric brain tumor patients receiving craniospinal irradiation. J Pediatr Endocrinol Metab (2014) 0.76
Development, implementation, and compliance of treatment pathways in radiation medicine. Front Oncol (2013) 0.76
Comparison study of intensity modulated arc therapy using single or multiple arcs to intensity modulated radiation therapy for high-risk prostate cancer. Radiat Oncol J (2013) 0.75
Volumetric modulated arc radiotherapy for limited osteosclerotic myeloma. World J Radiol (2013) 0.75
Clinical risk factors for late intestinal toxicity after radiotherapy: a systematic review protocol. Syst Rev (2013) 0.75
Treatment of MRI-Diagnosed Trigeminal Peripheral Nerve Sheath Tumors by Stereotactic Radiotherapy in Dogs. J Vet Intern Med (2016) 0.75
IMRT for head and neck cancer: reducing xerostomia and dysphagia. J Radiat Res (2016) 0.75
Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys (1991) 13.16
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol (2003) 11.94
Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC) Int J Radiat Oncol Biol Phys (1999) 6.16
Complication probability as assessed from dose-volume histograms. Radiat Res Suppl (1985) 3.85
Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys (1991) 3.64
The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol (2008) 1.93
Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations. Int J Radiat Oncol Biol Phys (1991) 1.89
Multivariable modeling of radiotherapy outcomes, including dose-volume and clinical factors. Int J Radiat Oncol Biol Phys (2006) 1.85
A test of the claim that plan rankings are determined by relative complication and tumor-control probabilities. Int J Radiat Oncol Biol Phys (1998) 1.63
Analysis of clinical complication data for radiation hepatitis using a parallel architecture model. Int J Radiat Oncol Biol Phys (1995) 1.54
Clinically relevant optimization of 3-D conformal treatments. Med Phys (1992) 1.42
Calculation of normal tissue complication probability and dose-volume histogram reduction schemes for tissues with a critical element architecture. Radiother Oncol (1991) 1.28
Value of whole brain re-irradiation for brain metastases--single centre experience. Clin Oncol (R Coll Radiol) (2007) 1.27
Optimization of uncomplicated control for head and neck tumors. Int J Radiat Oncol Biol Phys (1990) 1.26
Methodological issues in radiation dose-volume outcome analyses: summary of a joint AAPM/NIH workshop. Med Phys (2002) 1.20
Orbital lymphoma: is it necessary to treat the entire orbit? Int J Radiat Oncol Biol Phys (2004) 1.13
Results of re-irradiation for cerebral metastases. Cancer (1980) 1.10
Modeling the effects of inhomogeneous dose distributions in normal tissues. Semin Radiat Oncol (2001) 0.99
Clinical experience with retreatment for palliation. Semin Radiat Oncol (2000) 0.98
Physician/patient-driven risk assignment in radiation oncology: reality or fancy? Int J Radiat Oncol Biol Phys (1997) 0.96
Inter-tumor heterogeneity and radiation dose-control curves. Radiother Oncol (1987) 0.96
Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome. JAMA (2009) 9.47
EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol (2008) 5.46
Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol (2004) 4.63
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med (2013) 4.49
Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol (2005) 3.86
Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys (2010) 3.83
CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines. Radiother Oncol (2003) 3.78
Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys (2010) 3.73
Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys (2002) 3.64
Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2008) 3.61
Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol (2008) 3.55
Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys (2006) 3.40
Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys (2007) 3.34
High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys (2005) 3.32
Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol (2007) 3.16
Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol (2007) 3.08
Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol (2011) 3.04
Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys (2002) 2.76
Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys (2010) 2.69
Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys (2010) 2.66
Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol (2005) 2.65
Involved-field radiation therapy for inoperable non small-cell lung cancer. J Clin Oncol (2007) 2.56
Radiotherapy dose-volume effects on salivary gland function. Int J Radiat Oncol Biol Phys (2010) 2.48
Lack of osteoradionecrosis of the mandible after intensity-modulated radiotherapy for head and neck cancer: likely contributions of both dental care and improved dose distributions. Int J Radiat Oncol Biol Phys (2007) 2.48
Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol (2006) 2.45
Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. Int J Radiat Oncol Biol Phys (2003) 2.41
Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys (2012) 2.41
Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol (2010) 2.41
Radiation-associated liver injury. Int J Radiat Oncol Biol Phys (2010) 2.39
Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys (2010) 2.32
Lipid bilayer structure determined by the simultaneous analysis of neutron and X-ray scattering data. Biophys J (2008) 2.27
Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol (2012) 2.24
The presence of multiple regions of homozygous deletion at the CSMD1 locus in oral squamous cell carcinoma question the role of CSMD1 in head and neck carcinogenesis. Genes Chromosomes Cancer (2003) 2.24
Telomeric expression sites are highly conserved in Trypanosoma brucei. PLoS One (2008) 2.22
PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys (2007) 2.21
Acute skin toxicity following stereotactic body radiation therapy for stage I non-small-cell lung cancer: who's at risk? Int J Radiat Oncol Biol Phys (2008) 2.20
Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol (2005) 2.20
Parotid glands dose-effect relationships based on their actually delivered doses: implications for adaptive replanning in radiation therapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys (2013) 2.19
Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med (2010) 2.17
A microRNA expression signature for cervical cancer prognosis. Cancer Res (2010) 2.14
Radiation dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys (2010) 2.14
Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: safety profile for RTOG 0933. Radiother Oncol (2010) 2.12
Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res (2010) 2.11
A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol (2009) 2.10
Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol (2008) 2.08
Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys (2005) 2.02
Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol (2006) 2.00
Dose-effect relationships for the submandibular salivary glands and implications for their sparing by intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys (2008) 1.99
Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol (2003) 1.97
Volumetric modulated arc therapy: planning and evaluation for prostate cancer cases. Int J Radiat Oncol Biol Phys (2009) 1.97
Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck. Radiother Oncol (2006) 1.95
Intensity-modulated radiation therapy for head and neck carcinoma. Oncologist (2007) 1.94
Equatorially dominated magnetic field change at the surface of Earth's core. Science (2003) 1.94
Whole brain radiotherapy with hippocampal avoidance and simultaneously integrated brain metastases boost: a planning study. Int J Radiat Oncol Biol Phys (2007) 1.91
A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data. Int J Radiat Oncol Biol Phys (2007) 1.90
Design and implementation of an anthropomorphic quality assurance phantom for intensity-modulated radiation therapy for the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys (2005) 1.90
Integral radiation dose to normal structures with conformal external beam radiation. Int J Radiat Oncol Biol Phys (2006) 1.88
Partial volume tolerance of the liver to radiation. Semin Radiat Oncol (2005) 1.85
Multivariable modeling of radiotherapy outcomes, including dose-volume and clinical factors. Int J Radiat Oncol Biol Phys (2006) 1.85
Progress toward a microradiation therapy small animal conformal irradiator. Med Phys (2006) 1.84
GeneDB--an annotation database for pathogens. Nucleic Acids Res (2011) 1.82
Radiation dose-volume effects in the esophagus. Int J Radiat Oncol Biol Phys (2010) 1.78
Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. J Clin Oncol (2013) 1.78
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst (2010) 1.76
Measurement of lung tumor motion using respiration-correlated CT. Int J Radiat Oncol Biol Phys (2004) 1.74
A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood (2009) 1.74
Radiation-associated kidney injury. Int J Radiat Oncol Biol Phys (2010) 1.74
Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys (2010) 1.72
Analyzing habituation responses to novelty in zebrafish (Danio rerio). Behav Brain Res (2009) 1.69
Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol (2006) 1.69
Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters. Int J Radiat Oncol Biol Phys (2006) 1.67
Surveillance computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric Hodgkin's lymphoma: a report from the Children's Oncology Group. J Clin Oncol (2012) 1.67
Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. Int J Radiat Oncol Biol Phys (2005) 1.65
The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. Int J Radiat Oncol Biol Phys (2010) 1.65
Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int J Radiat Oncol Biol Phys (2004) 1.64
Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst (2012) 1.64
Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing. Int J Radiat Oncol Biol Phys (2009) 1.64
FGF9 suppresses meiosis and promotes male germ cell fate in mice. Dev Cell (2010) 1.64
A new method for synthesizing radiation dose-response data from multiple trials applied to prostate cancer. Int J Radiat Oncol Biol Phys (2009) 1.59
Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer (2005) 1.57
Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 1.56
Retrospective analysis of prostate cancer patients with implanted gold markers using off-line and adaptive therapy protocols. Int J Radiat Oncol Biol Phys (2005) 1.55
A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol (2007) 1.55